Top Esomeprazole Brands for Effective Heartburn Relief

Esomeprazole, a commonly used proton pump inhibitor, has been a go-to medication for individuals seeking relief from acid-related stomach issues. With its increasing popularity, several pharmaceutical brands have emerged as leading providers of this effective treatment. Selecting the right brand can be crucial to ensure the optimal benefits and reliability of the medication. To discover which brands stand out among the rest for their quality and customer satisfaction, read on for a comprehensive list below.

Illustration of esomeprazole

Best brands of esomeprazole in 2025

Nexium

Nexium, produced by AstraZeneca, is a leading brand in the esomeprazole market, generating significant revenues, such as $1.33 billion in 2021, primarily from emerging markets. It has been a dominant player since its FDA approval in 2002 for treating GERD and erosive esophagitis. Despite a decline in revenue due to generic versions, Nexium continues to see growth in markets like China and Japan. The brand has earned over $52.5 billion globally since its introduction. Its market share is supported by strategic agreements and product launches. For further insights into the esomeprazole market, you can explore the detailed market report.

Esomepra

Esomeprazole, particularly through brands like Nexium, is a leading medication in the market, driven by its effective acid control and rapid symptom relief. The global esomeprazole market, valued at USD 1.91 billion in 2023, is expected to grow at a CAGR of 5.35% from 2024 to 2033, with North America holding a significant 39.0% market share due to the high prevalence of GERD and advanced healthcare infrastructure. Key players such as AstraZeneca, with Nexium generating USD 1.33 billion in revenues in 2021, contribute to the market's growth. The market is also influenced by strategic developments and new product launches, while Asia Pacific is anticipated to be the fastest-growing region during the forecast period. For more detailed insights, visit the Esomeprazole Market Report.

Neksium

Nexium, a brand of esomeprazole produced by AstraZeneca, stands as a leading player in the proton pump inhibitor (PPI) market, generating significant revenues globally. In 2021, Nexium earned $1.33 billion, boasting a high market share in emerging economies. The brand has been the number one PPI in terms of cumulative prescriptions over the past decade. Despite the challenges posed by COVID-19, Nexium's sales have experienced a strong recovery due to increased product distribution, new launches, and strategic developments. The brand continues to dominate, especially in North America and Asia-Pacific, with growing demand driven by the rising prevalence of GERD. For more in-depth information, explore the Esomeprazole Market Report.

Esoz

Esoz is a notable brand in the production of esomeprazole, a proton pump inhibitor used to reduce digestive acid production. The Esoz 40 Tablet has been exported to 25 countries, with Singapore and the Dominican Republic being the largest importers, accounting for 42.82% and 11.27% of total exports, respectively. In 2014, the month of May saw the highest number of export shipments. The average export price for Esoz 40 Tablets was $5.99 under the relevant subchapter. The global esomeprazole market, which includes Esoz, is expected to grow at a CAGR of 5.35% from 2024 to 2033, driven by rising incidences of GERD.

Emeset

Esomeprazole, commonly known by the brand name Nexium, is a highly effective medication for treating gastroesophageal reflux disease (GERD) and peptic ulcers, but it is not associated with the brand "Emeset." However, if we consider the broader context of esomeprazole producers, key players like Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, and Viatris Inc. are prominent in the market. The global esomeprazole market, valued at USD 1.91 billion in 2023, is expected to grow at a CAGR of 5.35% from 2024 to 2033, with North America holding a significant 39.0% market share in 2023. The market is driven by the increasing prevalence of GERD, with approximately 20% of adults in North America affected. Advanced healthcare infrastructure and strategic developments by market players also contribute to the market's growth. For more detailed information, you can visit the Mordor Intelligence Esomeprazole Market Report.

Nexipride

Nexium, a brand of esomeprazole produced by AstraZeneca, is a leading player in the esomeprazole market, known for its efficacy in treating gastroesophageal reflux disease (GERD) and peptic ulcers. In 2021, Nexium generated revenues of USD 1.33 billion, with a significant share in emerging markets. The brand has seen market growth driven by strategic developments, new product launches, and increased prevalence of GERD, particularly in North America where it holds a 39% market revenue share. Esomeprazole's market is expected to grow at a CAGR of 5.2% to 5.35% from 2024 to 2032, with North America remaining the dominant region. The drug's success is also attributed to its high demand in the United States due to the significant number of individuals suffering from GERD and related ailments. For more detailed information, visit the AstraZeneca website.

Ession

Esomeprazole, a proton pump inhibitor, is predominantly produced by several key players, with AstraZeneca's Nexium being a prominent brand. Nexium, which contains esomeprazole, generated revenues of USD 1.33 billion in 2021, highlighting its significant market share. The brand's success is driven by the increasing prevalence of GERD, affecting approximately 20% of adults in North America. North America, particularly the United States, accounts for a substantial market share, with the region holding a 39.0% market revenue share in 2023. The market is expected to grow at a CAGR of 5.2% to 5.3% from 2024 to 2032. For more insights into the Esomeprazole market size, visit the detailed report.

Esofine

Esomeprazole, particularly under brands like Nexium, is a highly sought-after medication due to its efficacy in treating gastroesophageal reflux disease (GERD) and other acid-related disorders. The market for esomeprazole is expected to grow at a CAGR of 5.2%-5.35% from 2024 to 2029 or 2033, driven by increasing prevalence of GERD, especially in North America where it holds a significant market share of around 39% in 2023. Major players like Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, and Viatris Inc. are key contributors to this market. The rising aging population and altering lifestyles are also significant factors influencing demand. For instance, AstraZeneca's Nexium generated revenues of USD 1.33 billion in 2021, highlighting the market's potential. For more details on the esomeprazole market, you can visit Mordor Intelligence.

Heligen

Heligen, as a prominent producer of esomeprazole, stands out for its high-quality manufacturing processes and stringent quality control measures. The company ensures that its esomeprazole products, such as esomeprazole magnesium trihydrate, meet the rigorous standards set by regulatory bodies like the European Medicines Agency, with a high degree of crystallinity and enantiomeric purity controlled by HPLC on a chiral-AGP column. In the market, Heligen's products contribute to the growing demand for esomeprazole, particularly in regions like North America, where the market share for esomeprazole was around 39% in 2023. The global esomeprazole market, driven by rising cases of GERD, is expected to grow at a CAGR of 5.35% from 2024 to 2033, with Heligen likely to be a key player in this growth. The company's commitment to stability and quality is evident from the shelf-life specifications and stability data provided for its products.

Sompraz

Sompraz, a brand of esomeprazole, is a leading producer in the market, benefiting from the increasing prevalence of gastroesophageal reflux disease (GERD) which affects approximately 20% of adults in North America. The global esomeprazole market, valued at USD 1.91 billion in 2023, is expected to grow at a CAGR of 5.35% from 2024 to 2033. North America, driven by the U.S., holds the largest market share, with 39.0% of the global revenue in 2023. The market's growth is also fueled by the rising acceptance of novel drug delivery systems and strategic developments by key players. Companies like Teva Pharmaceutical Industries Ltd. and Viatris Inc. are significant competitors in this fragmented market. You can find more insights about the esomeprazole market.